KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) EBT Margin (2016 - 2025)

Emergent BioSolutions (EBS) has 15 years of EBT Margin data on record, last reported at 34.1% in Q4 2025.

  • For Q4 2025, EBT Margin fell 1992.0% year-over-year to 34.1%; the TTM value through Dec 2025 reached 11.15%, up 2818.0%, while the annual FY2025 figure was 11.15%, 2484.0% up from the prior year.
  • EBT Margin reached 34.1% in Q4 2025 per EBS's latest filing, down from 24.92% in the prior quarter.
  • Across five years, EBT Margin topped out at 48.47% in Q3 2024 and bottomed at 539.6% in Q2 2024.
  • Average EBT Margin over 5 years is 40.55%, with a median of 15.03% recorded in 2024.
  • Peak YoY movement for EBT Margin: crashed -46555bps in 2024, then skyrocketed 52768bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 34.97% in 2021, then plummeted by -159bps to 20.75% in 2022, then grew by 5bps to 19.7% in 2023, then grew by 28bps to 14.18% in 2024, then plummeted by -141bps to 34.1% in 2025.
  • Per Business Quant database, its latest 3 readings for EBT Margin were 34.1% in Q4 2025, 24.92% in Q3 2025, and 11.92% in Q2 2025.